The Guanylate Cyclase pipeline drugs market research report outlays comprehensive information on the Guanylate Cyclase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Guanylate Cyclase pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Cardiovascular, Ophthalmology, Genito Urinary System, and Central Nervous System which include the indications Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Glaucoma, Ocular Hypertension, Chronic Kidney Disease (Chronic Renal Failure), Focal Segmental Glomerulosclerosis (FSGS), Neuroinflammation, and MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes). It also reviews key players involved in Guanylate Cyclase targeted therapeutics development with respective active and dormant or discontinued products.
The Guanylate Cyclase pipeline targets constitutes close to 30 molecules. Out of which, approximately 26 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, and Preclinical stages are 6, 7, 4, and 9 respectively. Similarly, the universities portfolio in Preclinical, and Discovery comprises 3, and 1 molecule.
Guanylate Cyclase overview
Guanylate cyclase is an enzyme that catalyzes the synthesis of cyclic guanosine 3′,5′-monophosphate (cGMP) from guanosine 5′ triphosphate (GTP). Guanylate cyclase exists in both a membrane-bound and soluble form in the cell. It is a signal-transducing enzyme that responds to specific stimuli by synthesizing the second messenger cGMP. The cGMP in turn directly regulates many activities, including kinases, diesterases, and cyclic-nucleotide gated ion channels.
For a complete picture of Guanylate Cyclase’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
